SUBSCRIBE
SUBSCRIBE

Jazz Pharmaceuticals, Inc.

NEWS
3d illustration of a cancer cell and lymphocytes
Business
ImmunoGen Stock Climbs on Positive Ovarian Cancer Data
ImmunoGen, released positive efficacy and tolerability data from its FORWARD II trial of its mirvetuximab soravtansine in combination with Merck’s Keytruda in platinum-resistant epithelial ovarian cancer (EOC). Shares jumped almost 12 percent in premarket trading.
March 26, 2018
 · 
3 min read
 · 
Mark Terry
Tiny KalVista Explodes on $760 Million Deal With Drug Giant Merck & Co.
Business
Jazz Pharma Bets $175 Million on This Massachusetts Biotech’s Antibody-Drug Program
August 29, 2017
 · 
2 min read
Booming Jazz Pharma Inks Huge Lease in Philadelphia to Accommodate Growth
Job Trends
Booming Jazz Pharma Inks Huge Lease in Philadelphia to Accomodate Growth
July 7, 2017
 · 
2 min read
Should You Drop What You’re Doing And Buy Jazz Pharma Stock?
April 10, 2017
 · 
1 min read
What You Missed: Nippon Fine Chemical Formed Human Barricade to Stop FDA Employee
FDA Lashes Out at Jazz Pharma CMO for Continued Regulatory Violations
January 27, 2017
 · 
2 min read
Genetown
Jazz Pharma’s 841% Price Increase On A Sleep Drug Could Attract Attention From Capitol Hill
November 3, 2016
 · 
1 min read
Good or Bad? Pharma Bro Thinks Jazz Pharma Could be Worth $20 Billion, Calls Mast Therapeutics 'Worthless'
Biotech Beach
Good or Bad? Pharma Bro Thinks Jazz Pharma Could be Worth $20 Billion, Calls Mast Therapeutics ‘Worthless’
September 13, 2016
 · 
2 min read
Wall Street's Top Biotech Analyst Loves These 2 Life Science Stocks
Biotech Bay
4 Cheap Biotech Stocks Ready to Fly
August 16, 2016
 · 
4 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Biotech Bay
4 Movers & Shakers in This Year’s Oncology Market
June 15, 2016
 · 
3 min read
Load More
JOBS
IN THE PRESS
Biotech Bay
Jazz Pharmaceuticals to Participate in Upcoming November 2022 Investor Conferences
November 1, 2022
 · 
1 min read
Business
Jazz Pharmaceuticals to Report 2022 Third Quarter Financial Results on November 9, 2022
October 26, 2022
 · 
1 min read
Zymeworks To Host Conference Call on Exclusive Licensing Agreement of Zanidatamab
October 19, 2022
 · 
6 min read
BioForest
Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody
October 19, 2022
 · 
15 min read
Jazz Pharmaceuticals to Present Advancements in Sleep Medicine at Psych Congress 2022
September 15, 2022
 · 
12 min read
Biotech Bay
Jazz Pharmaceuticals to Participate in Upcoming September 2022 Investor Conferences
August 31, 2022
 · 
1 min read
Drug Development
Jazz Pharmaceuticals Announces Initiation of Phase 3 Trial Evaluating Epidiolex®/Epidyolex® (cannabidiol) for Patients with Epilepsy with Myoclonic-Atonic Seizures
August 18, 2022
 · 
6 min read
Business
Jazz Pharmaceuticals Announces Second Quarter 2022 Financial Results and Affirms 2022 Financial Guidance
August 3, 2022
 · 
42 min read
Business
Jazz Pharmaceuticals to Report 2022 Second Quarter Financial Results on August 3, 2022
July 20, 2022
 · 
1 min read
Drug Development
Jazz Pharmaceuticals Announces Top-line Results from Phase 3 Trial Evaluating Nabiximols Oromucosal Spray in Adult Participants with Multiple Sclerosis Spasticity
June 28, 2022
 · 
9 min read
Load More